GC starts P1 trials of hemophilia treatment - Korea Biomedical Review

GC starts P1 trials of hemophilia treatment  Korea Biomedical Review

GC said Thursday that it has administered the first dose of MG1113, a hemophilia treatment, to a patient participating in phase 1 clinical trial for the drug.